COMETRIQ® (Cabozantinib)

The FDA on November 29, 2012 approved COMETRIQ® for the treatment of patients with progressive metastatic medullary thyroid cancer (MTC). COMETRIQ®  is a small molecule that inhibits the activity of multiple tyrosine kinases, including RET, MET, and VEGF receptor 2. COMETRIQ® is available in capsule form and is a product of  Exelixis, Inc.